Corp-Pharmaceuticals are waiting until the epidemics are eminent before they even consider wasting research and production on antibiotics. This is not across the board of course, but the trend is there. Actually ‘saving’ the world is a low priority for corporations. making money once it gets really bad — well, that’s a profitable mode of operation.
Corp-Pharma = Evil.
“Antibiotic resistance is growing, and we are fast running out of treatment options. If we leave it to market forces alone, the new antibiotics we most urgently need are not going to be developed in time.”
WHO priority pathogens list for R&D of new antibiotics
Priority 1: CRITICAL
- Acinetobacter baumannii, carbapenem-resistant
- Pseudomonas aeruginosa, carbapenem-resistant
- Enterobacteriaceae, carbapenem-resistant, ESBL-producing
Priority 2: HIGH
- Enterococcus faecium, vancomycin-resistant
- Staphylococcus aureus, methicillin-resistant, vancomycin-intermediate and resistant
- Helicobacter pylori, clarithromycin-resistant
- Campylobacter spp., fluoroquinolone-resistant
- Salmonellae, fluoroquinolone-resistant
- Neisseria gonorrhoeae, cephalosporin-resistant, fluoroquinolone-resistant
Priority 3: MEDIUM
- Streptococcus pneumoniae, penicillin-non-susceptible
- Haemophilus influenzae, ampicillin-resistant
- Shigella spp., fluoroquinolone-resistant
How to cure this? (ha!)
Put a society funded (government) bounty on creating effective drugs that combat drug resistant bacteria — with a guaranteed production and delivery of N numbers of doses over X number of years, all at an agreed upon ‘society benefiting’ fixed price.
Penalize drug companies that do not participate by adding additional months of FDA approval time to any drugs on the docket.
“Hey, Drug Companies! Society needs this. You’re in the business. DO IT! Or find another means to fill your shareholder’s bank accounts.”